Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 101 to 125 of 360

Type: Guidance`Remove $Type: Guidance filter`

Guidance and quality standards awaiting development
Title	Type
Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]	Technology appraisal guidance
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]	Technology appraisal guidance
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Excimer Laser Trabeculotomy (ELT) for glaucoma	HealthTech guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]	Technology appraisal guidance
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]	Technology appraisal guidance
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]	Technology appraisal guidance
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance

Results per page

10
25
50
All